LIDOCAINE SOLUTION AND FOOT WIPE
A treatment solution contains a topical anesthetic, an anesthetic solvent, and a carrier fluid, wherein the treatment solution is essentially free of alcohol. A treatment solution contains an antifungal agent, a topical anesthetic, an antifungal agent solvent, and a carrier fluid, wherein the treatment solution is essentially free of alcohol. A treatment solution contains a topical anesthetic, an anesthetic solvent, and a carrier fluid, wherein the treatment solution has an alcohol content of 15 wt% or below of the total solution. A treatment solution contains an antifungal agent, a topical anesthetic, an antifungal agent solvent, and a carrier fluid, wherein the treatment solution has an alcohol content of 15 wt% or below of the total solution.
1 . A treatment solution, comprising:
a topical anesthetic;
an anesthetic solvent; and
a carrier fluid,
wherein the treatment solution is essentially free of alcohol.
2 . The treatment solution as claimed in claim 1 , wherein the anesthetic solvent comprises a heterocyclic acetal solvent.
3 . The treatment solution as claimed in claim 1 , wherein the anesthetic solvent comprises a solvent that is miscible with the carrier fluid.
4 . The treatment solution as claimed in claim 1 , wherein the anesthetic solvent comprises dioxolane.
5 . The treatment solution as claimed in claim 1 , wherein the topical anesthetic comprises one of lidocaine, benzocaine, tetracaine, pramoxine, and prilocaine.
6 . A treatment solution, comprising:
an antifungal agent;
a topical anesthetic;
an antifungal agent solvent; and
a carrier fluid,
wherein the treatment solution is essentially free of alcohol.
7 . The treatment solution as claimed in claim 6 , wherein the antifungal agent comprises a naphthyl thiocarbamate.
8 . The treatment solution as claimed in claim 6 , wherein the antifungal agent consists of at least one selected from the group comprising: clioquinol; haloprogin; miconazole nitrate; povidone iodine; undecylenic acid and its salts of calcium, copper, and zinc; and clotrimazole 1%.
9 . The treatment solution as claimed in claim 6 , wherein the antifungal agent comprises at least one selected from the group comprising: ketoconazole, an imidazole, (1-[4-(4-{ [(2R,4S)-2-(2,4-Dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-1-piperazinyl]ethanone); sulconazole, an imidazole (1-{2-[(4-Chlorobenzyl)sulfanyl]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole); sertaconazole, an imidazole (1-{2-[(7-Chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole); betamethasone ((11β,16β)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione) + clotrimazole, an imidazole (1-[(2-Chlorophenyl)(diphenyl)methyl]-1H-imidazole); ciclopirox (6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone); econazole (1-{2-[(4-Chlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole); naftifin ((2E)-N-Methyl-N-(1-naphthylmethyl)-3-phenyl-2-propen-1-amine); oxiconazole ((1Z)—N—[(2,4-Dichlorobenzyl)oxy]-1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethanimine); butenafine, a Trimethylamine, (N-Methyl-1-[4-(2-methyl-2-propanyl)phenyl]—N—(1-naphthylmethyl)methanamine); undecylenic acid + cholorozylenol (para-chloro-meta-xylenol); and terbinafine hydrochloride.
10 . The treatment solution as claimed in claim 6 , wherein the antifungal agent comprises tolnaftate.
11 . The treatment solution as claimed in claim 6 , wherein the antifungal agent solvent comprises a heterocyclic acetal solvent.
12 . The treatment solution as claimed in claim 6 , wherein the antifungal agent solvent comprises a solvent that is miscible with the carrier fluid.
13 . The treatment solution as claimed in claim 6 , wherein the antifungal agent solvent comprises dioxolane.
14 . The treatment solution as claimed in claim 6 , wherein the antifungal agent is tolnaftate having a concentration of at least 1 wt% of the total solution, and the antifungal agent solvent is dioxolane having a concentration in the range of 2 wt% to 4 wt% of the total solution.
15 . The treatment solution as claimed in claim 6 , wherein the topical anesthetic comprises one of lidocaine, benzocaine, tetracaine, pramoxine, and prilocaine. [note to Jesse: phenol?}.
16 . The treatment solution of claim 1 , wherein the treatment solution further includes at least one of: emollients, surfactants, essential oils, thickening agents, texturizers, preservatives, and exfoliants.
17 . The treatment solution of claim 10 , wherein the treatment solution further includes at least one of peppermint and eucalyptus.
18 . A treatment solution, comprising
a topical anesthetic;
an anesthetic solvent; and
a carrier fluid,
wherein the treatment solution has an alcohol content of 15 wt% or below of the total solution.
19 . The treatment solution as claimed in claim 18 , wherein the treatment solution has an alcohol content of one of 14 wt% or below, 13 wt% or below, 12 wt% or below, 11 wt% or below, 10 wt% or below, 9 wt% or below, 8 wt% or below, 7 wt% or below, 6 wt% or below, 5 wt% or below, 4 wt% or below, 3 wt% or below, and 2 wt% or below.
20 . The treatment solution as claimed in claim 18 , wherein the topical anesthetic comprises one of lidocaine, benzocaine, tetracaine, pramoxine, and prilocaine.
21 . A treatment solution, comprising
an antifungal agent;
a topical anesthetic;
an antifungal agent solvent; and
a carrier fluid,
wherein the treatment solution has an alcohol content of 15 wt% or below of the total solution.
22 . The treatment solution as claimed in claim 21 , wherein the treatment solution has an alcohol content of one of 14 wt% or below, 13 wt% or below, 12 wt% or below, 11 wt% or below, 10 wt% or below, 9 wt% or below, 8 wt% or below, 7 wt% or below, 6 wt% or below, 5 wt% or below, 4 wt% or below, 3 wt% or below, or 2 wt% or below.
23 . The treatment solution as claimed in claim 21 , wherein the topical anesthetic comprises one of lidocaine, benzocaine, tetracaine, pramoxine, and prilocaine.